engleski

Errare humanum est, sed in errare perseverare diabolicum: methodological errors in the assessment of the relationship between I-131 therapy and possible increases in the incidence of malignancies

The study by Kitahara et al. is again a fine example of a methodologically insufficient study nonetheless drawing wide-ranging conclusions which could and will, if not seen in the proper light, lead to potentially detrimental changes in therapy regimens of patients with hyperthyroidism. It remains therefore the case that in spite of nearly eight decades of intensive clinical use, still no study exists in literature which both shows a positive, oncogenic effect of I-131 therapy of benign thyroid disease and passes rigorous scrutiny of methodological sufficiency. Hence, until evidence from randomized trials has assessed the long-term prognostic impact of RAI, we are convinced and still believe that, as stated before for cancer, postoperative RAI remains an eminently sensible idea, not just for most DTC patients but also for patients with benign thyroid disease.

radioiodine, cancer, thyroid

nije evidentirano